A double-blind dose-escalating study of LT-3001 in healthy volunteers

Trial Profile

A double-blind dose-escalating study of LT-3001 in healthy volunteers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs LT 3001 (Primary)
  • Indications Stroke
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 03 Aug 2017 Planned number of patients changed to 80.
    • 03 Aug 2017 New trial record
    • 28 Jul 2017 According to a Lumosa Therapeutics media release, first human subject was dosed with LT3001 in California.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top